QiShenYiQi Pill for Myocardial Collagen Metabolism and Apoptosis in Rats of Autoimmune Cardiomyopathy

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2022 Apr 1

PMID 35361037

Authors

Shichao Lv

Wanqin Zhang

Peng Yuan

Chunmiao Lu

Jianping Dong

Junping Zhang

Affiliations

Soon will be listed here.

Abstract

Context: QiShenYiQi pill (QSYQ) is a traditional Chinese medicine with a myocardial protective effect.

Objective: To explore the effect of QSYQ on myocardial collagen metabolism in rats with autoimmune cardiomyopathy and explore the underlying mechanism from the aspect of apoptosis.

Materials And Methods: We established an autoimmune cardiomyopathy model using Lewis rats. The rats were then randomly divided into six groups (n = 8): control, model, 3-methyladenine (15 mg/kg, intraperitoneal injection), QSYQ low-dose (135 mg/kg, gavage), QSYQ medium dose (270 mg/kg, gavage), and QSYQ high-dose (540 mg/kg, gavage) for four weeks. Van Gieson staining was applied for myocardial pathological characteristics, TUNEL fluorescence for myocardial cell apoptosis, enzyme-linked immunosorbent assay (ELISA) for serum PICP, PIIINP, and CTX-I levels, and western blot analysis for type I/III myocardial collagen, Bcl-2, Bax, and caspase-3 proteins.

Results: Results showed that QSYQ (135, 270, or 540 mg/kg) significantly reduced the expression of myocardial type I/III collagen, and concentrations of serum PICP, PIIINP, and CTX-I in rats. Moreover, QSYQ could alleviate myocardial fibrosis more effectively at a higher dose. QSYQ could also inhibit myocardial apoptosis via downregulating Bcl-2 expression, and upregulating Bax and caspase-3 expression levels.

Discussion And Conclusions: The QSYQ can improve myocardial collagen metabolism by inhibiting apoptosis, which provides a potential therapeutic approach for autoimmune cardiomyopathy.

Citing Articles

Chinese and western medicine treatment of myocardial fibrosis drugs.

Zhu Y, Zhang F, Li Z, Zhou Y, Shu Y, Ruan J Front Cardiovasc Med. 2025; 11:1477601.

PMID: 39882321 PMC: 11774883. DOI: 10.3389/fcvm.2024.1477601.

The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications.

Li L, Zhang Y, Luo Y, Meng X, Pan G, Zhang H Drug Des Devel Ther. 2023; 17:771-790.

PMID: 36925998 PMC: 10013573. DOI: 10.2147/DDDT.S399423.

References

Grogan M, Redfield M, Bailey K, Reeder G, Gersh B, Edwards W . Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995; 26(1):80-4. DOI: 10.1016/0735-1097(95)00148-s. View

Westermann D, Savvatis K, Schultheiss H, Tschope C . Immunomodulation and matrix metalloproteinases in viral myocarditis. J Mol Cell Cardiol. 2009; 48(3):468-73. DOI: 10.1016/j.yjmcc.2009.08.019. View

Doyen D, Moceri P, Ducreux D, Dellamonica J . Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020; 395(10235):1516. PMC: 7180035. DOI: 10.1016/S0140-6736(20)30912-0. View

Cannata A, Artico J, Gentile P, Merlo M, Sinagra G . Myocarditis evolving in cardiomyopathy: when genetics and offending causes work together. Eur Heart J Suppl. 2019; 21(Suppl B):B90-B95. PMC: 6439912. DOI: 10.1093/eurheartj/suz033. View

Heymans S, Eriksson U, Lehtonen J, Cooper Jr L . The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol. 2016; 68(21):2348-2364. DOI: 10.1016/j.jacc.2016.09.937. View

Madjid M, Safavi-Naeini P, Solomon S, Vardeny O . Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020; 5(7):831-840. DOI: 10.1001/jamacardio.2020.1286. View

Lv S, Wu M, Li M, Wang Q, Xu L, Wang X . Effect and Mechanism of QiShenYiQi Pill on Experimental Autoimmune Myocarditis Rats. Med Sci Monit. 2016; 22:752-6. PMC: 4784548. DOI: 10.12659/msm.895655. View

Zeng X, Li L, Wen H, Bi Q . MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma. Mol Med Rep. 2016; 14(1):129-36. PMC: 4918621. DOI: 10.3892/mmr.2016.5208. View

Lopez B, Gonzalez A, Ravassa S, Beaumont J, Moreno M, San Jose G . Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol. 2015; 65(22):2449-56. DOI: 10.1016/j.jacc.2015.04.026. View

10.

Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J . Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol. 2019; 136:27-41. DOI: 10.1016/j.yjmcc.2019.09.001. View

11.

Wu Y, Tan H, Shui G, Bauvy C, Huang Q, Wenk M . Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 2010; 285(14):10850-61. PMC: 2856291. DOI: 10.1074/jbc.M109.080796. View

12.

Liu P, Mason J . Advances in the understanding of myocarditis. Circulation. 2001; 104(9):1076-82. DOI: 10.1161/hc3401.095198. View

13.

Vasilikos L, Spilgies L, Knop J, Wong W . Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins. Immunol Cell Biol. 2016; 95(2):160-165. DOI: 10.1038/icb.2016.118. View

14.

Xu X, Lai Y, Hua Z . Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2018; 39(1). PMC: 6340950. DOI: 10.1042/BSR20180992. View

15.

Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A . A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990; 57(2):250-62. DOI: 10.1016/0090-1229(90)90039-s. View

16.

Zhao L, Fu Z . Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy. J Immunol Res. 2018; 2018:5301548. PMC: 5964556. DOI: 10.1155/2018/5301548. View

17.

Zhang S, Wang H, Li L, Chang X, Ma H, Zhang M . Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes. J Cell Mol Med. 2019; 23(9):6393-6402. PMC: 6714141. DOI: 10.1111/jcmm.14527. View

18.

Bavishi C, Bonow R, Trivedi V, Abbott J, Messerli F, Bhatt D . Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Prog Cardiovasc Dis. 2020; 63(5):682-689. PMC: 7274977. DOI: 10.1016/j.pcad.2020.05.013. View

19.

Chen Y, Li Q, Pan C, Yan L, Fan J, He K . QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode. Sci Rep. 2015; 5:11802. PMC: 4488877. DOI: 10.1038/srep11802. View

20.

Zheng Q, Wei X, Pan C, Li Q, Liu Y, Fan J . QiShenYiQi Pills ameliorates ischemia/reperfusion-induced myocardial fibrosis involving RP S19-mediated TGFβ1/Smads signaling pathway. Pharmacol Res. 2019; 146:104272. DOI: 10.1016/j.phrs.2019.104272. View